FeesSafety
Pluang+

Labcorp CFO Julia Wang to speak at UBS Global Healthcare Conference Nov 10, webcast available.

Market News
04 Nov 2026, 15:00 WIB
PRNewsWire
View Source
Neutral
Labcorp CFO Julia Wang to speak at UBS Global Healthcare Conference Nov 10, webcast available.

Labcorp announced that its Chief Financial Officer, Julia Wang, will speak at the UBS Global Healthcare Conference on November 10 at 8:45 a.m. ET. The event will be accessible via a live audio webcast on Labcorp's Investor Relations website and will be archived for replay for 180 days. Labcorp is a global leader in laboratory services, supporting doctors, hospitals, and pharmaceutical companies with diagnostics and drug development. This presentation offers investors insight into Labcorp's strategies and performance in the healthcare sector.

Labcorp's CFO Julia Wang will speak at the UBS Global Healthcare Conference, providing insights into the company's strategies. For readers following the healthcare sector, here is Pluang's market snapshot as of Nov 04, 2026 19:41 WIB: Among 150 priced health-sector US stocks tradable on Pluang, 121 rose and 23 fell today. Notable movers include OSCR at USD 35.20 with a 1-day change of +8.61% and Pluang order activity of 16% Sell / 84% Buy, BRKR at USD 60.45 up +6.99%, and AMGN at USD 489.98 up +6.23% with 32% Sell / 68% Buy activity and a typical hold time of 73 days.

More News

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...

Market News
Bearish
25 minutes ago
Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...

Company Fundamentals
Bullish
25 minutes ago
ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...

Market News
Bullish
25 minutes ago
New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...

Others
Bullish
25 minutes ago
Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...

Market News
Bullish
25 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App